Finanzen von OrthoPediatrics Corp (KIDS)KIDSOrthoPediatrics Corp

OrthoPediatrics Corp (KIDS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Trauma and Deformity, accounting for 74.6% of total sales, equivalent to $52.63M. Other significant revenue streams include Scoliosis and Sports Medicine and Other. Understanding this composition is critical for investors evaluating how KIDS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, OrthoPediatrics Corp maintains a gross margin of 74.27%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.77%, while the net margin is -10.16%. These profitability ratios, combined with a Return on Equity (ROE) of -11.36%, provide a clear picture of how effectively KIDS converts its operational activities into shareholder value.

In the context of the broader market, KIDS competes directly with industry leaders such as CTKB and ANGO. With a market capitalization of $647.52M, it holds a significant position in the sector. When comparing efficiency, KIDS's gross margin of 74.27% stands against CTKB's 58.87% and ANGO's 50.87%. Such benchmarking helps identify whether OrthoPediatrics Corp is trading at a premium or discount relative to its financial performance.

OrthoPediatrics has shown significant revenue growth, with Q2 2026 revenue at $70.51 million, a 15.4% increase year-over-year. The gross margin is strong at 74%, indicating effective cost management, although the company continues to report net income losses.